SEC Form 4 · accession 0000899243-17-019209
AILERON THERAPEUTICS INC · ALRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian M. Gallagher Jr.
Director
Period of report
Jul 25, 2017
Accepted (ET)
Jul 27, 2017 · 6:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001420565
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $13.00 | Jul 25, 2017 | A | 20,000 | A | — | Jul 24, 2027 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1This option was granted on July 25, 2017. The shares underlying the option are scheduled to vest in equal annual installments over three years from July 25, 2017. The option was granted to the Reporting Person as director's compensation. As a Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, the Reporting Person is obligated to transfer any shares issued under the option to S.R. One, Limited, an indirect wholly-owned subsidiary of GlaxoSmithKline plc.